Stockscreener 앱 받기
88.34
0.97%
0.85
전일 마감가:
$87.49
열려 있는:
$89.55
하루 거래량:
2.42M
Relative Volume:
2.06
시가총액:
$7.67B
수익:
$688.00K
순이익/손실:
$-168.74M
주가수익비율:
-37.47
EPS:
-2.3577
순현금흐름:
$-185.87M
1주 성능:
+9.37%
1개월 성능:
+26.06%
6개월 성능:
+163.94%
1년 성능:
+485.81%
1일 변동 폭
$86.18
$90.99
1주일 범위
$80.72
$90.99
52주 변동 폭
$14.00
$90.99
Spyre Therapeutics Inc Stock (SYRE) Company Profile
명칭
Spyre Therapeutics Inc
전화
(617) 651-5940
주소
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
88.34 | 7.67B | 688.00K | -168.74M | -185.87M | -2.3577 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | Raymond James | Strong Buy |
| 2025-12-18 | 개시 | Mizuho | Outperform |
| 2025-12-17 | 개시 | Citigroup | Buy |
| 2025-09-26 | 개시 | Deutsche Bank | Buy |
| 2025-04-08 | 개시 | Leerink Partners | Outperform |
| 2025-03-18 | 개시 | Wolfe Research | Outperform |
| 2024-09-04 | 개시 | Wedbush | Outperform |
| 2024-07-16 | 개시 | Evercore ISI | Outperform |
| 2024-05-02 | 개시 | Robert W. Baird | Outperform |
| 2024-03-01 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-12-11 | 개시 | Guggenheim | Buy |
| 2023-12-11 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2019-03-21 | 개시 | JP Morgan | Overweight |
| 2018-09-04 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | 개시 | Evercore ISI | Outperform |
| 2018-03-14 | 재확인 | Needham | Buy |
모두보기
Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스
Spyre Therapeutics Inc (SYRE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Spyre Therapeutics Inc (SYRE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Spyre Therapeutics Inc (SYRE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Spyre’s Skyline-UC double win lifts hopes for IBD antibody combos - BioWorld News
Spyre Therapeutics Inc (SYRE) Institutional Confidence - TradingKey
Spyre Therapeutics Inc (SYRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Spyre Therapeutics Inc (SYRE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Spyre Therapeutics Inc (SYRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Spyre Therapeutics Inc (SYRE) Valuation: PE, PB & Fair Value Analysis - TradingKey
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $103 - Moomoo
Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Cogstate Ltd (COGZF) - The Globe and Mail
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $112 - Moomoo
Spyre Therapeutics (SYRE) Reveals Promising Results from SKYLINE Trial - GuruFocus
Wedbush Raises Price Target on Spyre Therapeutics to $100 From $80 on Positive SPY002 Results, Maintains Outperform Rating - marketscreener.com
Spyre reports positive phase 2 trial results for UC drug By Investing.com - Investing.com South Africa
Spyre reports positive phase 2 trial results for UC drug - Investing.com UK
Spyre says bowel disease drug cuts inflammation in mid-stage trial - Reuters
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients - The Manila Times
Spyre Therapeutics posts positive Phase 2 SKYLINE Part A results for SPY002, RHI -10.7 (p - TradingView
Spyre Therapeutics (NASDAQ: SYRE) posts positive Phase 2 SPY002 ulcerative colitis data - Stock Titan
Ulcerative colitis trial: Spyre drug sees 33% in remission at 12 weeks - Stock Titan
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $95 - Moomoo
Certain Common Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-JUN-2026. - marketscreener.com
Certain Restricted Stock Units of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-JUN-2026. - marketscreener.com
SYRE completes enrollment in SKYWAY basket study on SPY072, stock up - MSN
Spyre Therapeutics stock hits 52-week high at 79.75 USD By Investing.com - Investing.com Nigeria
Spyre Therapeutics stock hits 52-week high at 79.75 USD - Investing.com
Capital International Investors Purchases 1,100,000 Shares of Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics (SYRE) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Spyre Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Spyre Therapeutics grants inducement awards to four employees - scanx.trade
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics Grants Stock Options to Non-Executive Employees as Part of Equity Inducement Awards - Quiver Quantitative
Arrowpoint Investment Partners Singapore Pte. Ltd. Buys New Shares in Spyre Therapeutics, Inc. $SYRE - MarketBeat
SYRE Maintains Buy Rating by Deutsche Bank -- Price Target Raised to $115 - GuruFocus
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up - sharewise.com
Deutsche Bank Adjusts Spyre Therapeutics Price Target to $115 From $102, Maintains Buy Rating - marketscreener.com
Spyre Therapeutics (SYRE): 12 Best High Short Interest Stocks With Highest Upside Potential - Insider Monkey
Deutsche Bank raises Spyre stock price target on competitor setback By Investing.com - Investing.com South Africa
Deutsche Bank raises Spyre stock price target on competitor setback - Investing.com
Spyre Therapeutics CFO Scott Burrows sells $532,936 in stock By Investing.com - Investing.com South Africa
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therap - GuruFocus
Spyre Therapeutics Inc (SYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):